Published On: Wed, Sep 13th, 2017

Trinity Biotech Plc (NASDAQ:TRIB) – Latest Broker Consensus

Currently 4 brokers are covering Trinity Biotech plc (NASDAQ:TRIB), 1 rate it “Buy”, 3 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Below are the most recently updated broker updates which include ratings and price targets for Trinity Biotech plc (NASDAQ:TRIB).

10/05/2016 – Broker: Stephens Rating: equal weight downgrade

12/16/2015 – Broker: Roth Capital Rating: buy reiteration

10/23/2015 – Broker: Craig-Hallum Rating: hold New Target: 14 downgrade

09/03/2015 – Broker: Raymond James Rating: outperform New Target: 20 newcoverage

10/29/2014 – Broker: Zacks Rating: neutral New Target: 17.2 upgrade

11/19/2013 – Broker: Sidoti Rating: buy newcoverage

10/29/2013 – Broker: Jefferson Research Rating: hold downgrade

The average price target from the most recent broker reports is 17.07

The stock increased +1.29% (+0.07) during the last days session, reaching 5.48 and roughly 29202 shares were bought or sold by traders.

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech’s blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.